Zymeworks Inc. has been recruited by Denmark's Leo Pharma A/S to help discover and develop new bispecific antibodies for dermatology indications. That the deal's value could exceed $480 million might be the headliner for companies that have yet to capture big pharma's attention. Zymeworks, by contrast, has already inked technology deals with Merck & Co. Inc., Glaxosmithkline plc, Janssen Biotech Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co. and Celgene Corp.